Syntimmune Turns Drug For Rare Anemia Into $400M Alexion Buyout | Enterpreneurship
Syntimmune, a biotech startup formed by the veteran founders of the hemophilia drug developer Syntonix, has been acquired by Alexion Pharmaceuticals for $400 million in cash up front.
Syntimmune is right in Alexion’s (NASDAQ: ALXN) wheelhouse. The Boston-based firm is best known for eculizumab (Soliris), a drug for ultra-rare blood diseases. In buying Syntimmune, Alexion will acquire an experimental drug for a rare type of anemia, warm autoimmune hemolytic anemia (WAIHA). Beyond the upfront cash, Syntimmune’s shareholders, led by Apple Tree Partners, could see another $800 million in downstream payments if the drug progresses.
Syntimmune was formed in 2013 by… Read more »
UNDERWRITERS AND PARTNERS